You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
The Solana SARS-CoV-2 test can be run in batches of 11 samples, with minimum hands on time, no extraction, and results in approximately 25 minutes.
The GeneMe assay, called FRANKD, is currently being used to test Virgin Atlantic pilots and crew of certain routes departing Heathrow Airport.
The US Food and Drug Administration has granted an Emergency Use Authorization for a rapid, at-home COVID-19 test.
The loop-mediated isothermal amplification test runs on a battery-powered device to provide self-testing individuals with results in approximately 30 minutes.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.
The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.
The Pro-Lab Diagnostic Pro-AmpRT SARS-CoV-2 test consists of six primers and amplifies a 206 base-pair region of the ORF1ab gene of SARS-CoV-2.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.